Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis acquires Ebewe Pharma for 925m euros

Novartis acquires Ebewe Pharma for 925m euros

21st May 2009

Novartis has signed an agreement to acquire Ebewe Pharma for 925 million euros.

As well as helping the business expand, the deal will provide the former’s pharmaceutical division Sandoz with the chance to improve patient access to generic oncology medicines.

Carboplatin, methotrexate, epirubicin and paclitaxel are all examples of Ebewe Pharma’s products that are a vital part of treating a range of cancers.

Dr Daniel Vasella, Novartis’ chairman and chief executive officer, noted the deal will strengthen the company’s pipeline with a number of planned launches.

He added the inclusion of the treatments fits into the business’ strategy to help sufferers around the world receive therapies.

“These medicines will remain the backbone of multi-drug treatments in the fight against cancer, one of the world’s leading causes of death,” stated Dr Vasella.

Meanwhile, Novartis has gained exclusive worldwide rights to develop and commercialise QMF149 with an inhaled corticosteroid mometasone from Schering-Plough’s portfolio.

QMF149 is a fixed-combination of the company’s investigational QAB149 (indacaterol).

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.